Cannabidiol
- Generic Name
- Cannabidiol
- Brand Names
- Epidiolex, Sativex, Epidyolex
- Drug Type
- Small Molecule
- Chemical Formula
- C21H30O2
- CAS Number
- 13956-29-1
- Unique Ingredient Identifier
- 19GBJ60SN5
- Background
Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investig...
- Indication
When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications:
...
- Associated Conditions
- Multiple Sclerosis, Seizures, Severe Pain, Moderate Pain
- Associated Therapies
- -
Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2008-03-18
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 42
- Registration Number
- NCT00628290
- Locations
- 🇩🇪
University of Cologne, Dept. of Psychiatry and Psychotherapy, Cologne, NRW, Germany
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2008-01-09
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Yale University
- Target Recruit Count
- 41
- Registration Number
- NCT00588731
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.